Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

SAB Biotherapeutics, Inc.: Woodline Partners LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Woodline Partners LP amended its Schedule 13G filing for SAB Biotherapeutics, Inc., disclosing a revised passive stake in the clinical-stage biotech under SEC accession 0000919574-26-008061. The filing updates the investment firm's previously reported ownership position, though the amended document's headline did not specify the exact percentage or share count in the summary. The change matters because 13G amendments signal shifts in institutional ownership that can influence SAB's shareholder base and liquidity profile. Investors will watch for the full filing details to confirm whether Woodline increased or reduced its position and at what levels.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Woodline Partners LP, SAB Biotherapeutics, Inc.